ENOV — Enovis Share Price
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.01% | ||
| Return on Equity | n/a | ||
| Operating Margin | 2.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2009 | 2010 | 2011 | 2012 | 2013 | 2014E | 2015E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 79.23 | 148 | 193.74 | 218.56 | 255.58 | n/a | n/a | 34.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
Directors
- Mitchell Rales CHM (64)
- Matthew Trerotola PRE (53)
- Christopher Hix CFO (59)
- Brady Shirley CEX (55)
- Patricia Lang CHO (59)
- Shyam Kambeyanda EVP (50)
- Daniel Pryor EVP (53)
- Bradley Tandy SVP (62)
- Patrick Allender LED (74)
- Thomas Gayner IND (59)
- Rhonda Jordan IND (63)
- Liam Kelly IND (54)
- Philip Okala IND (52)
- A. Clayton Perfall IND (62)
- Didier Teirlinck IND (64)
- Rajiv Vinnakota IND (50)
- Sharon Wienbar IND (59)
- Last Annual
- December 31st, 2013
- Last Interim
- September 30th, 2014
- Incorporated
- February 25th, 1998
- Public Since
- May 8th, 2008
- No. of Shareholders
- 1,177
- No. of Employees
- 7,367
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 57,107,950
- Address
- 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON, 19808
- Web
- https://www.enovis.com/
- Phone
- +1 3022529160
- Auditors
- Ernst & Young LLP
Upcoming Events for ENOV
Q1 2025 Enovis Corp Earnings Release
Enovis Corp Annual Shareholders Meeting
Enovis Corp Annual Shareholders Meeting
Q2 2025 Enovis Corp Earnings Release
Similar to ENOV
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Enovis share price?
As of Today at 20:27 UTC, shares in Enovis are trading at $35.10. This share price information is delayed by 15 minutes.
How has the Enovis share price performed this year?
Shares in Enovis last closed at $35.10 and the price had moved by -36.3% over the past 365 days. In terms of relative price strength the Enovis share price has underperformed the S&P500 Index by -41.2% over the past year.
What are the analyst and broker recommendations for Enovis?
There is no consensus recommendation for this security.
Find out moreWhat is the Enovis dividend yield?
Enovis does not currently pay a dividend.
Does Enovis pay a dividend?
Enovis does not currently pay a dividend.
When does Enovis next pay dividends?
Enovis does not currently pay a dividend.
How do I buy Enovis shares?
To buy shares in Enovis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enovis?
As of the previous close price of $35.10, shares in Enovis had a market capitalisation of .
Where are Enovis shares listed?
Here are the trading details for Enovis:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ENOV
What kind of share is Enovis?
Based on an overall assessment of its quality, value and momentum Enovis is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enovis share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Enovis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enovis. Over the past six months, its share price has underperformed the S&P500 Index by -7.49%.
As of the last closing price of $35.10, shares in Enovis were trading -17.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enovis PE Ratio?
The Enovis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $35.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enovis?
Enovis' management team is headed by:
- Mitchell Rales - CHM
- Matthew Trerotola - PRE
- Christopher Hix - CFO
- Brady Shirley - CEX
- Patricia Lang - CHO
- Shyam Kambeyanda - EVP
- Daniel Pryor - EVP
- Bradley Tandy - SVP
- Patrick Allender - LED
- Thomas Gayner - IND
- Rhonda Jordan - IND
- Liam Kelly - IND
- Philip Okala - IND
- A. Clayton Perfall - IND
- Didier Teirlinck - IND
- Rajiv Vinnakota - IND
- Sharon Wienbar - IND